Faes Farma Reports 9M Revenue Up 24%, EBITDA Up 17%
Faes Farma reaffirmed its 2026 guidance and reported net debt of approximately €260 million. EBITDA rose 20% excluding restructuring costs.
Faes Farma reported its 9M 2026 financial results, highlighting a 24% increase in revenue and a 17% rise in EBITDA, which reached 20% when excluding restructuring costs. The company reaffirmed its full-year 2026 guidance, noting that strong international performance and the successful integration of SIFI have effectively offset the impact of bilastine losses in the Japanese market. Additionally, the company reported accelerated cash generation and a net debt position of approximately €260 million.